碳纤维可调可重复使用配件降低乳腺癌放疗危及器官与正常组织剂量
这项试点研究纳入30例仰卧位下皱襞≥1 cm或侧方下垂的乳腺癌患者,比较标准定位与碳纤维可调可重复使用配件(CARA)支持乳房的全乳放疗计划。CARA消除所有下皱襞并降低同侧肺V20Gy、乳房V105%和身体V50%,不牺牲靶区覆盖,兼容深吸气屏气。
要点
- CARA消除所有下皱襞并降低同侧肺V20Gy、乳房V105%和身体V50%。
- CARA不牺牲靶区覆盖,与深吸气屏气兼容。
- CARA将开展随机对照试验进一步研究。
核心结论
- CARA可降低乳房V105%、肺和正常组织剂量,消除下皱襞,不牺牲靶区覆盖。
研究设计与样本
- 试点研究(NCT04543851),30例下皱襞≥1 cm或侧方下垂的仰卧位乳腺癌患者分别以标准定位和CARA支持乳房进行计划。
- 20例接受全乳伴或不伴区域淋巴结放疗,方案为42.5 Gy/16次或50 Gy/25次,使用CARA。
- 研究中位体重指数为32。
主要发现
- 全乳放疗同侧肺V20Gy中位数(范围)为标准定位12.3%(1.4%-28.7%)vs CARA 10.9%(1.2%-17.3%),Wilcoxon P=.005。
- 乳房V105%中位数为标准定位8.0%(0.0%-29%)vs CARA 4.0%(0.0%-23%),P=.006。
- 身体V50%中位数为标准定位3056 mL(1476-5285 mL)vs CARA 2780 mL(1415-5123 mL),P=.001。
- CARA兼容深吸气屏气,所有左乳腺癌患者心脏V25Gy中位数为0.1%(范围0%-1.9%)。
- CARA皮肤反应与历史数据一致,日常治疗摆位变异与标准仰卧位一致。
关键数值与推荐
- CARA消除所有下皱襞。
- 全乳放疗同侧肺V20Gy中位数CARA为10.9%(范围1.2%-17.3%)。
- 乳房V105%中位数CARA为4.0%(范围0.0%-23%)。
- 身体V50%中位数CARA为2780 mL(范围1415-5123 mL)。
- 左乳腺癌患者心脏V25Gy中位数为0.1%(范围0%-1.9%)。
临床怎么用
- 对仰卧位下皱襞≥1 cm或侧方下垂、高体重指数的乳腺癌患者,可考虑使用CARA支持乳房以降低危及器官和正常组织剂量。
- CARA可与深吸气屏气联合用于左乳腺癌放疗。
局限性
- 为试点研究,样本量30例,其中20例接受CARA放疗。
- CARA尚需随机对照试验进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This pilot study (ClinicalTrials.gov NCT04543851) investigates a novel breast positioning device using a low density, high tensile carbon-fiber cradle to support the breast, remove the inframammary fold, and reduce dose to organs at risk for whole breast radiation therapy in the supine position. METHODS AND MATERIALS: Thirty patients with inframammary folds ≥1 cm or lateral ptosis in supine treatment position were planned with standard positioning and with a carbon-fiber Adjustable Reusable Accessory (CARA) breast support. Twenty patients received whole breast with or without regional nodal irradiation with 42.5 Gy in 16 fractions or 50 Gy in 25 fractions using CARA. Median body mass index was 32 in this study. RESULTS: CARA removed all inframammary folds and reduced V20Gyipsilateral lung, V105%breast, and V50% body, without compromising target coverage. Median (range) V20Gyipsilateral lung for whole breast radiation therapy was 12.3% (1.4%-28.7%) with standard of care versus 10.9% (1.2%-17.3%) with CARA (Wilcoxon P = .005). Median V105% breast was 8.0% (0.0%-29%) with standard of care versus 4.0% (0.0%-23%) with CARA (P = .006) and median V50% body was 3056 mL (1476-5285 mL) versus 2780 mL (1415-5123 mL) with CARA (P = .001). CARA was compatible with deep inspiration breath hold and achieved median V25Gyheart = 0.1% (range 0%-1.9%) for all patients with left breast cancer. Skin reactions with CARA were consistent with historical data and daily variation in treatment setup was consistent with standard supine positioning. CONCLUSIONS: CARA can reduce V105%breast, lung and normal tissue dose, and remove the inframammary fold for breast patients with large or pendulous breasts and high body mass index treated in the supine position, without compromising target coverage. CARA will undergo further study in a randomized controlled trial.
引用
- Duzenli C, Koulis T, Menna T, et al. Reduction in Doses to Organs at Risk and Normal Tissue During Breast Radiation Therapy With a Carbon-Fiber Adjustable Reusable Accessory. Pract Radiat Oncol. 2021. PMID: 34303034. doi:10.1016/j.prro.2021.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。